CD25 as a unique marker on human basophils in stable-mildly symptomatic allergic asthma.
CD25
basophils
ex vivo stimulation
immunophenotype
stable-mildly symptomatic allergic asthma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
08
2022
accepted:
13
12
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Basophils in acute asthma exacerbation are activated as evidenced by their increased expression levels of activation markers such as CD203c and CD63. However, whether basophils of allergic asthmatics who are in stable phase and have no asthma exacerbations display a specific and distinctive phenotype from those of healthy individuals has yet to be well characterized. We aimed to identify the phenotype of basophils from allergic asthmatics in the stable phase and investigate whether such a phenotype is affected by We determined by flow cytometry, the expression of surface proteins such as CD25, CD32, CD63, CD69, CD203c, and CD300a and intracellular anti-apoptotic proteins BCL-2, BCL-xL, and MCL-1. We investigated these markers in blood basophils obtained from well-characterized patients with stable-mildly symptomatic form of allergic asthma with no asthma exacerbation and from healthy individuals. Moreover, we determined In contrast to all tested markers, CD25 was significantly increased on circulating basophils in the patient cohort with stable-mildly symptomatic allergic asthma than in healthy controls. The expression levels of CD25 on blood basophils showed a tendency to positively correlate with FeNO levels. Notably, CD25 expression was not affected by Our data identifies CD25 as a unique marker on blood basophils of the stable phase of allergic asthma but not of asthma exacerbation as mimicked by
Sections du résumé
Background
UNASSIGNED
Basophils in acute asthma exacerbation are activated as evidenced by their increased expression levels of activation markers such as CD203c and CD63. However, whether basophils of allergic asthmatics who are in stable phase and have no asthma exacerbations display a specific and distinctive phenotype from those of healthy individuals has yet to be well characterized.
Objective
UNASSIGNED
We aimed to identify the phenotype of basophils from allergic asthmatics in the stable phase and investigate whether such a phenotype is affected by
Methods
UNASSIGNED
We determined by flow cytometry, the expression of surface proteins such as CD25, CD32, CD63, CD69, CD203c, and CD300a and intracellular anti-apoptotic proteins BCL-2, BCL-xL, and MCL-1. We investigated these markers in blood basophils obtained from well-characterized patients with stable-mildly symptomatic form of allergic asthma with no asthma exacerbation and from healthy individuals. Moreover, we determined
Results
UNASSIGNED
In contrast to all tested markers, CD25 was significantly increased on circulating basophils in the patient cohort with stable-mildly symptomatic allergic asthma than in healthy controls. The expression levels of CD25 on blood basophils showed a tendency to positively correlate with FeNO levels. Notably, CD25 expression was not affected by
Conclusion
UNASSIGNED
Our data identifies CD25 as a unique marker on blood basophils of the stable phase of allergic asthma but not of asthma exacerbation as mimicked by
Identifiants
pubmed: 36685514
doi: 10.3389/fimmu.2022.1031268
pmc: PMC9849741
doi:
Substances chimiques
Allergens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1031268Informations de copyright
Copyright © 2023 Iype, Rohner, Bachmann, Hermann, Pavlov, von Garnier and Fux.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Respir J. 2006 Sep;28(3):513-22
pubmed: 16737985
J Immunol. 2009 Feb 15;182(4):2432-8
pubmed: 19201898
Am J Respir Crit Care Med. 2011 Sep 1;184(5):602-15
pubmed: 21885636
J Immunol. 1991 Jul 1;147(1):237-42
pubmed: 1711077
Am J Respir Crit Care Med. 2008 Nov 15;178(10):1002-8
pubmed: 18787222
J Immunol. 1999 Feb 1;162(3):1717-22
pubmed: 9973434
Eur J Immunol. 2003 Apr;33(4):834-9
pubmed: 12672048
J Exp Med. 1993 Mar 1;177(3):605-11
pubmed: 8436904
Blood. 1996 Oct 15;88(8):3028-37
pubmed: 8874201
J Allergy Clin Immunol. 2002 May;109(5):817-23
pubmed: 11994706
J Allergy Clin Immunol. 2010 Feb;125(2):483-489.e3
pubmed: 20159259
J Leukoc Biol. 2017 Jan;101(1):227-238
pubmed: 27443880
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6813-7
pubmed: 1697689
Am J Respir Crit Care Med. 1994 Oct;150(4):1086-93
pubmed: 7921441
Blood. 2009 Feb 12;113(7):1526-34
pubmed: 18955562
J Exp Med. 1990 Dec 1;172(6):1577-82
pubmed: 1701820
Respir Res. 2016 Jan 14;17:5
pubmed: 26762527
Allergy. 2017 Oct;72(10):1532-1539
pubmed: 28474352
J Allergy Clin Immunol. 2001 Feb;107(2):265-71
pubmed: 11174192
Clin Exp Allergy. 2017 Jan;47(1):71-84
pubmed: 27910206
Cell Death Differ. 2018 Jan;25(1):204-216
pubmed: 28960207
Eur J Immunol. 1996 Oct;26(10):2493-8
pubmed: 8898965
Allergy. 2017 Oct;72(10):1583-1586
pubmed: 28426171
J Allergy Clin Immunol. 2018 Nov;142(5):1647-1650.e3
pubmed: 30048671
Am J Respir Crit Care Med. 2000 May;161(5):1473-8
pubmed: 10806141
Cytokine. 2020 Mar;127:154934
pubmed: 31783259